What is GNMSF stock price today?

GNMSF (Genmab A/S) stock is trading at $330.37 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GNMSF stock going up or down today?

GNMSF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GNMSF stock now?

The decision to buy GNMSF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GNMSF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GNMSF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GNMSF stock overvalued or undervalued?

GNMSF currently trades at a P/E ratio of 14.47, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if GNMSF is fairly priced.

What is GNMSF's P/E ratio?

GNMSF has a price-to-earnings (P/E) ratio of 14.47, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is GNMSF's market cap?

GNMSF (Genmab A/S) has a market capitalization of $20.35 billion, making it a mid-cap stock.

What is GNMSF's price to book ratio?

GNMSF trades at a price-to-book (P/B) ratio of 3.54, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GNMSF pay dividends?

GNMSF does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is GNMSF's dividend yield?

GNMSF does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is GNMSF stock a good long-term investment?

GNMSF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GNMSF's revenue growth rate?

GNMSF has shown revenue growth of 0.2% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, GNMSF is profitable with a profit margin of 0.4%. This indicates the company generates 0.4 cents of profit for every dollar of revenue.

What are the risks of investing in GNMSF?

Key risks for GNMSF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GNMSF compare to its competitors?

Compare GNMSF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GNMSF's performance and positioning.

What is GNMSF's stock price target for 2026?

Our AI model provides price targets for GNMSF based on fundamental analysis: Bull case $429.48 (+30%), Base case $379.93 (+15%), Bear case $297.33 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GNMSF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GNMSF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GNMSF's next earnings report?

GNMSF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GNMSF - Genmab A/S

NYSE * Healthcare * Biotechnology

$330.37

$-5.88 (-1.75%)

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, Anthropic PBC, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

GNMSF Key Statistics

Market Cap

$20.35B

P/E Ratio

14.47

P/B Ratio

3.54

EPS

$22.83

Revenue Growth

+0.2%

Profit Margin

0.4%

Employees

2,681

How GNMSF Compares to Peers

GNMSF has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

GNMSF has the highest profit margins in Biotechnology

GNMSF has the fastest revenue growth among competitors

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
GNMSF(This stock)	$20.35B	14.5	0%	0.4%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.12B	15.0	0%	0.2%	vs BIIB

Genmab A/S Company Information

Headquarters: Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500, undefined
Website: www.genmab.com
Sector: Healthcare
Industry: Biotechnology

About Genmab A/S

GNMSF Key Statistics

How GNMSF Compares to Peers

Genmab A/S Company Information

Upcoming Events for GNMSF